Zentalis Pharmaceuticals (ZNTL) Deferred Taxes (2022 - 2023)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Deferred Taxes of -$756000.0 for Q2 2023, down 1121.62% year-over-year from $74000.0 in Q2 2022, and down 679.38% quarter-over-quarter from -$97000.0 in Q1 2023.
Powered by 
Analysis
Zentalis Pharmaceuticals (ZNTL) Deferred Taxes (2022 - 2023) Analysis & Trends
Zentalis Pharmaceuticals' Deferred Taxes history runs 2 years deep, the most recent figure standing at -$756000.0 for Q2 2023.
- In Q2 2023, Deferred Taxes fell 1121.62% year-over-year to -$756000.0; the TTM figure through Mar 2024 stood at -$756000.0 (up 4.55% YoY), while the FY2023 annual figure was -$853000.0, down 10.92% from the prior year.
- Deferred Taxes for Q2 2023 stood at -$756000.0, down from -$97000.0 in the prior quarter.
- The five-year high for Deferred Taxes was $74000.0 in Q2 2022, with the low at -$769000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Zentalis Pharmaceuticals | 282.81 Mn | 282.81 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | -756,000.00 |
| Mar 31, 2023 | -97,000.00 |
| Dec 31, 2022 | -769,000.00 |
| Jun 30, 2022 | 74,000.00 |
| Mar 31, 2022 | -74,000.00 |